

CAR T-Cells Detection

Revolutionizing precision in Flow Cytometry
with our **BrightStep™ Technology**
CD19 & BCMA

 **50 min
PROTOCOL**



Compatible with
+30
antibody
panels

ADVANTAGES


- 1 High Resolution Identification**
- 2 Compatible with any Flow Cytometer**
- 3 Consistency and Reproducibility**
- 4 Specificity and Sensitivity**
- 5 Secondary Reagents Not Needed**
- 6 Simple 50 min. Protocol**



Do you want more information?
Scan this QR code and see
all the details of our
CAR T-Cell reagent.

> PRINCIPLE OF METHOD



BrightStep™: our cutting-edge labeling technology revolutionizing CAR T-Cell Detection:



BrightStep™ advanced conjugation technology **enhances fluorescent signal strength** while **preserving the protein's conformation and natural modifications (CD19 and BCMA)**. This ensures unparalleled sensitivity performance without compromising the recognition of the protein by CAR T-Cell chimeric antigen receptors.

> REAGENT PERFORMANCE

Bar graph representing the SI data obtained from different samples (Yescarta - DLBCL, Yescarta - FL, & Academic CAR T-Cells - DLBCL) labeling with Immunostep reagent comparing it with reagents from other competitors.



Dot plots representing the sample (C: academic CAR T-Cells) extracted from the bar graph demonstrate the superior discriminatory ability of Immunostep reagent over its competitors.

Evaluation of Immunostep CD19 reagent's efficiency using clinical samples from various commercial and academic sources, including CAR T-Cell therapies like Yescarta, across different cancer diseases. Comparative analyses with competitors reagents were conducted. Despite variability in CAR expression levels, Immunostep consistently outperformed its competitors in accurately discriminating between negative and positive populations, especially in challenging samples.

> PROTOCOL 50min

